$1.24
-0.02[-1.59%]
At close: Apr 18
$1.24
0[0.00%]
After Hours: 4:23PM EDT
InflaRx
(NASDAQ:IFRX)Latest News for InflaRx Stock (NASDAQ:IFRX)
InflaRx Stock (NASDAQ: IFRX)
Categories: All
Friday, March 22, 2024
Thursday, March 21, 2024
- InflaRx's INF904 Will Initially Target Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, With Initiation Of A Phase 2a PK Dose-ranging Study Expected By The End Of 2024, With Data Availability Anticipated In 2025Benzinga Newsdesk - Mar 21, 2024, 7:15AM
- InflaRx Will Focus Development Activities And Resources Initially On Selected Indications In Immuno-dermatology, With Registrational-phase Vilobelimab And INF904Benzinga Newsdesk - Mar 21, 2024, 7:14AM
- InflaRx FY EPS €(0.78) Down From €(0.67) YoY, Sales €63.09KBenzinga Newsdesk - Mar 21, 2024, 7:13AM
- Earnings Scheduled For March 21, 2024Benzinga Insights - Mar 21, 2024, 6:15AM
Wednesday, March 20, 2024
Friday, January 26, 2024
Thursday, January 25, 2024
Thursday, January 04, 2024
- InflaRx shares are trading higher after the company reported topline results from the multiple ascending dose Phase 1 study with C5aR inhibitor INF904.Benzinga Newsdesk - Jan 4, 2024, 11:33AM
- InflaRx Reports Topline Results From Multiple Ascending Dose Part Of Its Randomized, Double-blind, Placebo-controlled Phase I Trial For INF904; To Advance INF904 Into Phase II Clinical DevelopmentBenzinga Newsdesk - Jan 4, 2024, 7:03AM
Monday, November 06, 2023
Friday, November 03, 2023
Thursday, November 02, 2023
Tuesday, September 12, 2023
Monday, September 11, 2023
Thursday, August 31, 2023
Wednesday, August 30, 2023
Friday, August 11, 2023
Thursday, August 10, 2023
Friday, June 30, 2023
Monday, June 12, 2023
Tuesday, May 16, 2023
Friday, May 12, 2023
Friday, April 21, 2023
Wednesday, April 12, 2023
Tuesday, April 11, 2023
Thursday, April 06, 2023
- Analyst Expectations for InflaRx's FutureBenzinga Insights - Apr 6, 2023, 2:01PM
- Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market BreakthroughVandana Singh - Apr 6, 2023, 1:49PM
- Walmart To Rally 14%? Here Are 10 Other Analyst Forecasts For ThursdayLisa Levin - Apr 6, 2023, 7:53AM
- Raymond James Maintains Strong Buy on InflaRx, Raises Price Target to $25Benzinga Newsdesk - Apr 6, 2023, 4:35AM
Wednesday, April 05, 2023
- Dow Rises 80 Points; MarketAxess Holdings Shares SlideLisa Levin - Apr 5, 2023, 2:33PM
- Watching InflaRx; Shares Moving Higher, Raymond James Out With A Note Increasing Price Target To $25 On Covid AuthorizationHappy Mohamed - Apr 5, 2023, 2:07PM
- Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Apr 5, 2023, 1:33PM
- Guggenheim Upgrades InflaRx to Buy, Announces $8 Price TargetBenzinga Newsdesk - Apr 5, 2023, 1:01PM
- Nasdaq Tumbles 150 Points; Liminal BioSciences Shares Spike HigherLisa Levin - Apr 5, 2023, 12:04PM
- HC Wainwright & Co. Reiterates Buy on InflaRx, Raises Price Target to $10Benzinga Newsdesk - Apr 5, 2023, 11:02AM
- Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023Benzinga Insights - Apr 5, 2023, 11:00AM
- InflaRx Shares Resume Trade Following Circuit Breaker HaltHappy Mohamed - Apr 5, 2023, 10:20AM
- InflaRx Shares Halted On Circuit Breaker To Downside; Stock Now Up 60.2%Happy Mohamed - Apr 5, 2023, 10:16AM
- MorphoSys, Nuburu And Other Big Stocks Moving Higher On WednesdayLisa Levin - Apr 5, 2023, 10:15AM
- InflaRx Shares Resume Trading Following Circuit Breaker HaltHappy Mohamed - Apr 5, 2023, 10:14AM
- InflaRx Shares Halted On Circuit Breaker To Upside; Stock Now Up 74.5%Happy Mohamed - Apr 5, 2023, 10:09AM
- Markets Mixed; US Trade Deficit Widens In FebruaryLisa Levin - Apr 5, 2023, 9:51AM
- InflaRx Shares Resume Trading; Up 42% For SessionBenzinga Newsdesk - Apr 5, 2023, 9:37AM
- InflaRx Shares Halted On Circuit Breaker To Upside; Up 49%Benzinga Newsdesk - Apr 5, 2023, 9:33AM
- InflaRx shares are trading higher on continued upward momentum after the company yesterday announced it received FDA EUA for Gohibic for the treatment of critically ill COVID-19 patients. Today, LifeSci Capital upgraded the stock from Market Perform to Outperform.Benzinga Newsdesk - Apr 5, 2023, 9:30AM
- LifeSci Capital Upgrades InflaRx to OutperformBenzinga Newsdesk - Apr 5, 2023, 9:09AM
- InflaRx Scores FDA Emergency Use Nod For COVID AntibodyVandana Singh - Apr 5, 2023, 9:06AM